Summary
Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company which conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.
Portola Pharmaceuticals Inc (PTLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Portola Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Portola Pharma Secures US$89 Million In Financing 13
Private Equity 15
Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 15
Partnerships 16
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 16
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 17
Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 18
Aciex Amends Research Agreement With Portola Pharma 19
Licensing Agreements 20
Portola Pharma Enters into Licensing Agreement with SRX Cardio 20
Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 21
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 22
Equity Offering 24
Portola Pharma Prices Public Offering of Shares for USD349.3 Million 24
Portola Pharma Prices Public Offering of Shares for USD150 Million 26
Portola Pharma Prices Public Offering of Shares for USD100 Million 28
Portola Pharma Raises USD185.3 Million in Public Offering of Shares 30
Portola Pharma Completes Public Offering Of Shares For US$106 Million 32
Portola Pharma Completes IPO For US$140 Million 33
Portola Pharmaceuticals Inc - Key Competitors 35
Portola Pharmaceuticals Inc - Key Employees 36
Portola Pharmaceuticals Inc - Locations And Subsidiaries 37
Head Office 37
Recent Developments 38
Financial Announcements 38
Aug 09, 2017: Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 38
May 08, 2017: Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 40
Feb 28, 2017: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 41
Nov 07, 2016: Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 43
May 05, 2016: Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update 45
May 05, 2016: Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 47
Feb 26, 2016: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update 49
Product News 51
05/23/2016: Portola Pharmaceuticals Announces Upcoming Data Presentation on AndexXa (andexanet alfa) at International Society on Thrombosis and Haemostasis 2016 Scientific and Standardization Committee Meeting 51
Product Approvals 52
Aug 19, 2016: Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa (andexanet alfa), a Factor Xa Inhibitor Antidote 52
Aug 17, 2016: Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa (andexanet alfa) 53
Feb 17, 2016: Portola Pharmaceuticals Announces Biologics License Application for Andexanet Alfa Accepted for Review by FDA 54
Clinical Trials 55
Nov 28, 2016: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition 55
Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 56
Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List Of Tables
List of Tables
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Portola Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Portola Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Portola Pharma Secures US$89 Million In Financing 13
Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 15
Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 16
Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 17
Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 18
Aciex Amends Research Agreement With Portola Pharma 19
Portola Pharma Enters into Licensing Agreement with SRX Cardio 20
Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 21
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 22
Portola Pharma Prices Public Offering of Shares for USD349.3 Million 24
Portola Pharma Prices Public Offering of Shares for USD150 Million 26
Portola Pharma Prices Public Offering of Shares for USD100 Million 28
Portola Pharma Raises USD185.3 Million in Public Offering of Shares 30
Portola Pharma Completes Public Offering Of Shares For US$106 Million 32
Portola Pharma Completes IPO For US$140 Million 33
Portola Pharmaceuticals Inc, Key Competitors 35
Portola Pharmaceuticals Inc, Key Employees 36
List Of Figures
List of Figures
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Portola Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
